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ny Need for Preoperative
ardiac Testing in
ntermediate-Risk Patients With
ight Beta-Adrenergic Blockade?*
im A. Eagle, MD, FACC,
ei C. Lau, MD
nn Arbor, Michigan
merging evidence-based care dictates the importance of
ccurate preoperative cardiac risk assessment, risk stratifica-
ion, and modification of risk parameters that guide the
ramework for optimum perioperative risk reduction strategies.
ontemporary approaches to the preoperative cardiac risk
ssessment use the guidelines published by the American
ollege of Cardiology/American Heart Association (ACC/
HA) (1). However, these guidelines did not incorporate the
ost recent perioperative risk-stratification approach in the
election of noninvasive cardiac testing and medical treat-
ent in the intermediate-risk patients. There is a general
onsensus that intermediate-risk preoperative patients
hould be identified and risk stratified with a clinical tool
uch as the revised cardiac risk index (2). Preoperative
oninvasive cardiac testing should be reserved for those
atients with multiple clinical predictors of risk or other
odifying factors. The paradigm is shifting for supporting
erioperative medical preventive therapy in the intermediate-
o high-risk patients with revised cardiac risk index 2
ithout documented severe myocardial ischemia (3–5).
See page 964
ptimal medical preventive therapy with agents such as
erioperative beta blockers (and possibly statins) is not yet
ully delineated, because there are very few large adequately
owered randomized controlled trials (RCTs) to provide
efinitive evidence for benefits and risks of perioperative
eta blockers.
In this issue of the Journal, Poldermans et al. (6) report
esults from a large study that challenge the preoperative
uidelines of the ACC/AHA (1) surrounding the use of
oninvasive cardiac testing for stable intermediate-risk pa-
*Editorials published in the Journal of American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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ational Institutes of Health National Heart, Lung, and Blood Institute, Pfizer,
anofiAventis, and the Robert Wood Johnson Foundation.ients. By using excellent beta-blocker therapy with tight
eart rate (HR) control of 60 to 65 beats/min, there was
rotection against major cardiac events after vascular sur-
ery, and noninvasive cardiac testing added little prognostic
alue among intermediate-risk patients in this setting. A
otal of 770 intermediate-risk preoperative patients receiv-
ng perioperative beta-blocker with targeted HR 60 to 65
eats/min who were undergoing major vascular surgery were
andomized to noninvasive cardiac testing or no testing.
he group that received preoperative noninvasive cardiac
esting was stratified into no ischemia, limited ischemia, and
xtensive ischemia on the basis of dobutamine stress echo-
ardiography findings. Prophylactic preoperative coronary
evascularization was dictated by study protocol and offered
nly to the group with extensive stress-induced ischemia.
he decision for coronary revascularization was at the
iscretion of the treating physician on the basis of subjective
valuation of coronary angiography and the perceived risks
f a potential delay in the index vascular surgical procedure.
There was no significant difference in the primary end
oint (composite postoperative cardiac death and/or nonfa-
al myocardial infarction [MI]) between preoperative car-
iac testing and no-testing. The incidence of the 30-day
omposite end point of cardiac death and nonfatal MI was
ow (2.2%), regardless of cardiac testing or no-testing.
atients that were able to achieve a preoperative HR 65
eats/min with beta-blocker had a lower incidence of the
rimary end point at 30 days and on long-term follow-up.
Despite these findings and other studies highlighting the
rotective benefit of tight beta blockade, uncertainty re-
ains: 1) what degree of abnormality seen on preoperative
oninvasive cardiac testing should result in consideration for
nvasive cardiac testing and potential coronary revascular-
zation?; 2) although the incidence of the primary end point,
.2%, is apparently low enough to dissuade testing in the
ntermediate-risk patients, this study and others have not
een adequately powered to establish with confidence a 25%
isk reduction by tight beta-blockade therapy (7); and 3) is
he observed protective effect of beta blocker solely a
echanism of “tight” HR and/or blood pressure control
elow the ischemic threshold, or is it a combined effect with
erioperative statin therapy?
Evidence increasingly discourages the need for routine
reoperative noninvasive cardiac testing strategy for most
ntermediate-risk preoperative patients. The selection of
oninvasive cardiac stress tests for the occasional patient
hould anticipate that the patient will meet guidelines for
oronary revascularization after coronary angiography, and
o testing is recommended when it might delay surgical
ntervention for urgent or emergent conditions. It is impor-
ant to realize that dobutamine echocardiography and nu-
lear perfusion stress testing for perioperative MI or death
ave excellent negative predictive values (near 100%) but
oor positive predictive values (20%) (1). A negative study
s reassuring in that the probability of a perioperative cardiac
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September 5, 2006:970–2 Editorial Commentvent is very small, but a positive study is still a relatively
eak predictor of a perioperative cardiac event. The study
y Poldermans et al. (6) did not address this issue, and the
tudy is underpowered to detect any potential benefit of
reoperative cardiac testing with “the intent to treat” (re-
ascularization) to reduce perioperative cardiac risk and/or
ong-term risk. To study the positive predictive value of
oninvasive cardiac testing, randomization would need to be
t the level of revascularization in an adequately sampled
opulation with a positive stress test. The CARP (Coronary
rtery Revascularization Prophylaxis) trial (8) comes closest
o this criteria but was also probably underpowered.
Consensus guidelines recommend that aggressive medical
anagement to provide myocardial protection in the peri-
perative state be a central element in reducing the cardiac
isk. Two historical RCTs (9,10) that demonstrated that
erioperative beta-blocker therapy was associated with im-
roved outcome in surgical patients at risk for coronary artery
isease are currently challenged by recent data (11,12). Today,
here is still debate to precisely define the optimal use of
erioperative beta blockers. Poldermans et al. (6) reported
hat the incidence of the 30-day end point in intermediate-
isk patients with tight beta blockade was 2.2% or 17 events
f 770 intermediate-risk patients. Tight HR control was
lso associated with a reduction in perioperative ischemia by
5%. However, the certainty with which one can trust this
linical strategy is tempered by the fact that there have been
ery few events among all patients enrolled in perioperative
eta-blocker RCTs (13,14). The findings reported by
oldermans et al. (6) in this issue of the Journal establish a
ealistic (25%) risk reduction by tight beta-blockade, but the
onfidence limits surrounding this point estimate are broad.
Poldermans et al. (6) had previously reported that an
ffective beta-adrenergic blockade regimen that kept the
R to 60 to 65 beats/min could be used to prevent the HR
rom exceeding an “ischemic threshold” detected by preop-
rative electrocardiography monitoring (15). The potential
echanisms of benefit for beta-blockers include prolonga-
ion of the coronary diastolic filling time, reduction in risk
f ischemic ventricular arrhythmias, and prevention of
isruption of previously quiescent atheromatous plaques
rom unopposed sympathetic stimulation that might com-
licate major noncardiac surgery (16). The mechanism of a
ardioprotective effect of beta-blockers could also be due to
nti-inflammatory effects or a blunting of proinflammatory
ffects (17). Although plausible in theory, there is currently
nsufficient information to recommend the routine incorpo-
ation of tight HR control with beta blocker in all preop-
rative patients at intermediate risk. More definitive indi-
ations for perioperative beta-blocker prophylaxis await
he results of the ongoing POISE (Perioperative Ischemia
valuation) trial.
A recent expedited update on the ACC/AHA guideline
ocusing on perioperative beta-blocker therapy has been
ublished (18) for the purpose of clarifying the current
ecommendations for national quality initiatives like the vhysicians Consortium for Performance Improvement and
he Surgical Care Improvement Project with regard to use
f beta-blockers. The updated ACC/AHA guidelines (18)
eflect the fact that preoperative beta-blocker treatment
ecommendations for noncardiac surgery to prevent periop-
rative cardiac complications are based on very few RCTs
ith which to answer several critical questions. What are
he beneficial effects of different beta-blocker agents? How
hould the medications be titrated? What is an optimal
osing regimen? What route of administration is optimal?
hat are the risks?
Poldermans et al. (6) reported that 42% to 43% of the
ntermediate-risk patients received statins preoperatively in
ombination with tight beta-blockade in both the testing
nd no testing group. Two retrospective trials have shown
n association between perioperative statin therapy and
ecreased perioperative cardiac complications (19,20). In
ddition a small prospective randomized trial that compared
torvastatin versus placebo for patients undergoing major
ascular surgery (21) demonstrated an 18% reduction (8%
s. 26%, respectively) in cardiac death, nonfatal MI, and
schemic stroke in the group that received atorvastatin.
hus, whether the observed beneficial perioperative risk
revention effect demonstrated by Poldermans et al. (6) can
e explained by the tight beta-blocker therapy alone or in
ombination with pleiotropic and anti-inflammatory effects of
tatins and beta-blockade is not known. Definitive indications
or a perioperative combination therapy with statin and beta-
locker prophylaxis awaits the efficacy result of the ongoing
ECREASE-IV (Dutch Echocardiographic Cardiac Risk
valuation Applying Stress Echo-IV) trial.
The current ACC/AHA guideline recommendations for
erioperative beta-blocker therapy (18) suggest using beta
lockers for the following situations: 1) should be continued
n all high-risk patients previously receiving beta-blocker
herapy undergoing vascular surgery; 2) should be adminis-
ered to all high-risk patients identified by myocardial
schemia on preoperative assessment undergoing vascular
urgery; 3) probably recommended for high-risk patients
efined by multiple clinical predictors undergoing
ntermediate- or high-risk procedures; 4) might be consid-
red for intermediate-risk patients defined by a single
linical predictor undergoing intermediate- or high-risk
rocedures; 5) might be considered in low-risk patients
efined by clinical predictors not receiving beta-blocker
herapy undergoing vascular surgery; and 6) should not be
dministered in preoperative patients with absolute contra-
ndications to beta-blocker.
Finally, the real message here is that patients with stable
oronary artery disease, receiving effective medical therapy,
ave low risk. In contrast, these data do not apply to
nstable patients, where increasingly the evidence suggests
hat aggressive medical and interventional treatment pro-
ides optimal coronary outcomes.
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